Member Info for Patience001

..also, if I were a holder of their funds and they were expressing concerns over their investment decision on a company that they had only just added to the fund .....I think I'd be more than concerned

Scriv - all I can say is you have a poor opinion of doctors.... off label prescribing is heavily regulated since you don't appear to understand

Not forgetting Polar's top up.....

Just to give credit where credit is due.....pretty spot on assessment yesterday by TornadoTony....

Agreed...with this level of pi action....

09-Dec-20 17:40:54 82.50 2 Sell* 76.00 112.00 1.65

.....you guys need to be sent for training .....you're so predictable....tiresome

Taverham /Computer909 - I do believe at the time a COVID focus was pursued that it was a good course of action, we were all thinking 'as-is' development pathways and timing for vaccines. I believe regulators and governments including agencies like the EMA and NIHR etc were encouraging ALL development options in the early months not knowing who or what would be delivered. Its right as developments emerge and we see where progress is deliverying that the course out of Covid is corrected. The SNG board can see this and I would expect them to course correct appropriately and not pursue this to no end.

Matml74

I've given thought to the lack of uptake on SNG001 by both government and regulators for some time now, incredulous as to how other treatments have been championed and not the IFN - beta product with its safety profile and use in MS etc. I really can't see a stock piling of SNG as a Covid treatment - it's not on the radar and can't see how RM will get it over that hurdle. I believe the science of SNG 001 as a COPD/ Asthma treatment for patients with a severe viral infection and believe that strategy should be refocused and an admission that we've missed the boat for this specific viral infection.

PMarrin, not sure I share your sentiment that nothing has changed similar to when the sp was 40p. SNG has since focused its efforts on Covid and away from COPD. Raised £80m to support a COVID ph3 study......and this was when the outcome of vaccines trials and the consequences of success there wasn't on many people's radar. Well we have 3 vaccines and government planning 'at risk' to conduct mass vaccinations in the hope that we can start to emerge from the pandemic. I'd say that this changes sentiment significantly. I would like to see the SNG board make a statement to tell its shareholders why it will continue to pursue a Covid treatment for SNG 0001 and why it would not revert back to its original COPD /Asthma indication.

That Morning Star list only gives the FUNDS which hold shares. There is an institutions tab which if you click on has nothing listed. I'm assuming until this becomes public ally available information MS doesn't have.

I would have expected that anyone who acquired the threshold level in the placing would have declared so already as i suspect they may have looked to do what we suspect Polar did since the vaccine announcements and averaged down. I can only suspect that the number of ii's doing so was extensive and at a low level....

Skyfarmer - I believe it had something to do with the fact that SNG didn't have the sufficient manufacturing capacity and hence trial materials available ....timing and readiness unfortunately have been challenging for SNG and acknowledged by the board. Also, the nebuliser has been changed which was originally a Phillips supplied device and we don't know really what was behind that!

P3 start - Q42020 and not November!

..also if she is feeling unwell, I'm sure having to be taught the technology would be a barrier.....I hope things work out for her.

...maybe he should have thought about that before he allowed Trump to make a muppet out of him...

https://endpts.com/covid-19-roundup-hahn-to-make-all-eua-data-public-sinovac-vaccine-triggers-quick-immune-response-study/

..also interesting in this article about questions around the Sinovac vaccine - “The protective efficacy of CoronaVac remains to be determined.”

Pretty damning article in the BMJ .....I guess we've raised it so often on this board in frustration, to see it stated in such a journal is shocking!

Cant believe 15.4M shares were traded and we ended up where we did.....

I agree! The Clinigen MAP was signed off at the end of Sept, there should be some data available on take-up, unless its not good.

Ghia, totally agree. And anyone listening to Prof Tan in the briefing knows there is much work yet to be done to get this over the line. Commercial scale manufacturing of vaccines - each batch needs to be individually quality approved and authorised, bioreactor processe variability can be an issue - CT will have been done using the same batch - 42k doses ; and by all accounts I would love to see the transportation study data for this vaccine - neg 70deg conditions..... I topped up on the drop today

Let's hope with Fauci back on central stage in the US Covid fight.....therapeutics get the focus as an immediate focus in the fight....